FLT4

ENSG00000037280
Target class
Kinase
Chromosome
5
Approved drugs
12
Clinical candidates (approved and in development)
47

Approved drugs
12
ClinGen gene-disease validity
Definitive
Clinical candidates (approved and in development)
47

Chemical probe available
Yes

Target name
FLT4
Gene name
Fms related receptor tyrosine kinase 4
Gene symbol
FLT4
Protein name
Vascular endothelial growth factor receptor 3 (VEGFR-3) (EC 2.7.10.1) (Fms-like tyrosine kinase 4) (FLT-4) (Tyrosine-protein kinase receptor FLT4)

  • VEGFR3
  • PCL
  • VEGFR-3

Gene biotype
Protein coding
Gene family
Receptor tyrosine kinases|I-set domain containing
Target class
Kinase
Target type
Human gene

Tissues expressed in
50
Protein localisation evidence grade
Supported
Highest tissue expression
64.05
Tissue specificity (Gini)
0.545
Tissue specificity (tau)
0.853

KEGG gene identifiers
  • hsa:2324
Protein interaction confidence
0.841533
Protein interaction partners
75

  • R-HSA-195399
  • R-HSA-9013695
  • R-HSA-9856530

End position
180649629
Start position
180601506
Chromosome
5
Strand
Reverse

Ensembl gene ID
ENSG00000037280
HGNC ID
HGNC:3767
www.genenames.org
NCBI Gene ID
2324
UniProt ID
P35916

  • Cell membrane
  • Single-pass type I membrane protein. Cytoplasm . Nucleus . Note=Ligand-mediated autophosphorylation leads to rapid internalization. .
  • SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
  • Single-pass type I membrane protein. Note=Ligand-mediated autophosphorylation leads to rapid internalization.
  • SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
  • Single-pass type I membrane protein.
  • SUBCELLULAR LOCATION: [Isoform 3]: Secreted. Cytoplasm.
  • Centrosome
  • Cytosol
  • Plasma membrane

Tissue specificity (tau)
0.853316
Expression inequality (Gini)
0.545183

Expression in transcripts per million

Thyroid
64.05
Lung
34.8
Spleen
31.3
Breast - Mammary Tissue
28.92
Adipose - Visceral (Omentum)
28.68

Expression in transcripts per million

  • Thyroid64.05
  • Lung34.8
  • Spleen31.3
  • Breast - Mammary Tissue28.92
  • Adipose - Visceral (Omentum)28.68
  • Fallopian Tube25.32
  • Cervix - Ectocervix23.8
  • Adipose - Subcutaneous22.45
  • Uterus21.5
  • Cervix - Endocervix21.29
  • Kidney - Medulla21.03
  • Kidney - Cortex19.79
  • Pituitary15.98
  • Adrenal Gland13.56
  • Small Intestine - Terminal Ileum12.35
  • Vagina11.92
  • Prostate11.45
  • Esophagus - Gastroesophageal Junction10.24
  • Esophagus - Muscularis9.77
  • Nerve - Tibial8.95
  • Bladder8.92
  • Testis8.67
  • Ovary8.37
  • Colon - Sigmoid8.22
  • Artery - Coronary7.65

And 29 more, listed on the interactive page.

  • heart disease

    Studies

    • preclinical: Highly important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Crucial in angiogenesis and the heart’s response to pressure overload; antihypertensive effects

    Biological samples

    • cardiovascular system
    PubMed 21283106
    pubmed.ncbi.nlm.nih.gov

  • regulation of catalytic activity

    Studies

    • biochemical: NVS_ENZ_hVEGFR3, is one of one assay component(s) measured or calculated from the NVS_ENZ_hVEGFR3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (3,763)

Drugs (51)